Worth Venture Partners’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Worth Venture Partners’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,673	Closed	-$201K	–	141
2020 Q2	$201K	Sell	4,673 -1,904	-29%	-$78.7K	0.1%	95
2020 Q1	$237K	Buy	6,577 +1,066	+19%	+$45.4K	0.15%	69
2019 Q4	$252K	Sell	5,511 -703	-11%	-$27.9K	0.12%	66
2019 Q3	$221K	Sell	6,214 -797	-11%	-$29.6K	0.13%	68
2019 Q2	$279K	Sell	7,011 -1,624	-19%	-$63.9K	0.15%	58
2019 Q1	$359K	Buy	8,635 +133	+2%	+$5.41K	0.2%	60
2018 Q4	$310K	Buy	8,502 +3,871	+84%	+$165K	0.23%	58
2018 Q3	$25K	Buy	+4,631	New	+$219K	0.02%	149
2018 Q1	–	Sell	-5,191	Closed	-$226K	–	133
2017 Q4	$226K	Buy	+5,191	New	+$221K	0.25%	71
2017 Q2	–	Sell	-6,469	Closed	-$271K	–	153
2017 Q1	$271K	Buy	+6,469	New	+$264K	0.24%	85

Other funds holding XPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Worth Venture Partners's XPH Position: Q3 2020 in Review

Worth Venture Partners sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q3 2020, closing a stake of 4,673 shares — an estimated $201K sold.

Worth Venture Partners first reported a position in XPH in Q1 2017 and held it in 10 quarters. The position peaked at $359K in Q1 2019. 72 funds tracked by Wall St. Rank hold XPH as of Q3 2020.

Worth Venture Partners reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q3 2020 after selling out during the quarter.
Worth Venture Partners sold 4,673 State Street SPDR S&P Pharmaceuticals ETF shares in Q3 2020, an estimated $201K.
Worth Venture Partners first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2017 and held it in 10 quarters.
Worth Venture Partners's State Street SPDR S&P Pharmaceuticals ETF position peaked at $359K in Q1 2019.
72 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q3 2020.

Based on Worth Venture Partners's 13F filing for Q3 2020, filed 16 Nov 2020.